Microbiota intestinal: impacto en la enfermedad metabólica

Contenido principal del artículo

Mayra Daniela Delgado Cruz
Abigail Gissela Yugcha Carpio
María Soledad Cedeño Veintimilla
Pedro Gerargo de los Ríos Tomalá
Jenniffer Katherine Molina Peñaherrera

Resumen

La microbiota del intestino cumple una serie de funciones metabólicas e inmunológicas en el ser humano, lo que permite buen estado de salud. Se conoce actualmente las implicaciones que tiene la alteración de la microbiota intestinal y la respuesta adversa del hospedero a estos cambios (disbiosis) sobre las enfermedades metabólicas. El sobrepeso y la obesidad constituyen factores de riesgo para un gran número de enfermedades crónicas, como el síndrome metabólico, la diabetes, las enfermedades cardiovasculares y algunos tipos de cáncer. Es así como el desequilibrio en la composición de la microbiota intestinal se han asociado a una mayor susceptibilidad a las infecciones y los trastornos de base inmunológica y, recientemente, también a la resistencia a la insulina y al aumento del peso corporal. En relación a la evidencia actual, resulta importante investigar los efectos en la modificación de la microbiota intestinal, mediante el uso alimentos funcionales probióticos y prebióticos, a fin de intervenir y prevenir el desarrollo de la obesidad y las alteraciones metabólicas.

Detalles del artículo

Cómo citar
1.
Delgado Cruz MD, Yugcha Carpio AG, Cedeño Veintimilla MS, de los Ríos Tomalá PG, Molina Peñaherrera JK. Microbiota intestinal: impacto en la enfermedad metabólica. Rev. Med. UCSG [Internet]. 26 de mayo de 2020 [citado 29 de marzo de 2024];21(1):52-60. Disponible en: https://rmedicina.ucsg.edu.ec/index.php/ucsg-medicina/article/view/1110
Sección
Artículos de Revisión
Biografía del autor/a

Mayra Daniela Delgado Cruz, Hospital del Instituto Ecuatoriano de Seguridad Social Dr. Teodoro Maldonado Carbo.

Dra. Mayra Daniela Delgado Cruz

Médico especialista en Medicina Interna

Médico tratante del Servicio de Urgencias

Hospital del Instituto Ecuatoriano de Seguridad Social Dr. Teodoro Maldonado Carbo.

Citas

Alteraciones de la microbiota intestinal y la respuesta adversa del hospedero a estos cambios J.F. Petrosino, S. Highlander, R.A. Luna, et al. Metagenomic pyrosequencing and microbial identification. Clin Chem, 55 (2009), pp. 856-866 http://dx.doi.org/10.1373/clinchem.2008.107565 | Medline

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabol-ic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Cardiol Rev. 2005; 13(6): 322-327.

Ferrer B, Dalmau J. Reflexiones sobre el síndrome metabólico. Acta Pediatr Esp. 2008; 66(3): 77-82.

Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R, et al. New scientific paradigms for probiotics and prebiotics. JClin Gastr. 2003; 37: 105-118.

Sanz Y, Nadal I, Sánchez E. Probiotics as drugs against human gastrointestinal infections. Rec Pat Anti-Infect Drug Disc. 2007; 2: 148-156.

Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6: 772-783.

Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57: 1.470-1.481.

Hooper LV, Midtvedt T, Gordon JI. How hostmicrobial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002; 22: 283-307. 2.

Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Desing 2003; 9: 175-191. 3.

Fanaro S, Chierici R, Guerrini P, Vigi V. Intestinal microflora in early infancy: composition and development. Acta Pae-diatr supl 2003; 441: 48-55.

Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69: 1.052S-1.057S.

Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519.

Schiffrin EJ, Blum S. Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S60-4.

Hara AM, Shanahan F.. The gut flora as a forgotten organ. EMBO Rep. 2006 Jul;7(7):688-93.

Weng M, Walker W. Bacterial colonization, probiotics, and clinical disease. J Pediatr. 2006 nov; 149(5): S 107-S114.

Toole PW, Claesson MJ. Gut microbiota : changes throughout the lifespan from infancy to elderly. Int Dairy J. 2010 Apr; 20(4): 281-91.

Hooper LV. Bacterial contributions to mammalian gut development. Trends Microbiol. 2004;12(3):129-34.

DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible rela-tionship with obesity. Mayo Clin Proc. 2008;83(4):460-9.

Macpherson AJ, Hunziker L, McCoy K, Lamarre A. IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect. 2001;3(12):1021-35.

Cebra JJ, Jiang HQ, Boiko N, Tlaskalova-Hogenova H. The role of mucosal microbiota in the development, maintenance, and pathologies of the mucosal immune system. In: Mestecky J, Lamm ME, Strober W, editors. Mucosal immunology. 3rd ed. Burlington, MA : Elsevier; 2005. p. 335-368.

Montalto M, D’Onofrio F, et al. Intestinal microbiota and its functions. Dig Liver Dis suppl. 2009 Jul; 3(2):30-4

Ouwehand AC, Vaughan EE, editors. Gastrointestinal microbiology. New York : Informa Healthcare; 2006.

Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009 Jan; 136(1):65-80.

Savage DC. Mucosal microbiota. In: Mestecky J, Lamm ME, Strober W, editors. Mucosal immunology. 3rd ed. Burlington, MA : Elsevier; 2005, p. 19-33.

Tungland BC, Meyer D. Nondigestible oligoand polysaccharides (dietary fiber): their physiology and role in human health and food. Comprehensive Reviews in Food Science and Food Safety 2002; 1: 73-92.

Teitelbaum JE, Walker WA. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu Rev Nutr 2002; 22: 107-138.

Mahida YR. Microbial-gut interactions in health and disease. Epithelial cell responses. Best Pract Res Clin Gastroenterol. 2004 Apr; 18(2):241-53.

Brandtzaeg P, Kiyono H, Pabst R, Russell MW. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol. 2008;1(1):31-7.

O’Hara AM, Shanahan F.. The gut flora as a forgotten organ. EMBO Rep. 2006 Jul;7(7):688-93.

Thompson-Chagoyán OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (ibd): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr. 2005 Jun; 24(3):339-52.

Denise K. Importance of microbial colonization of the gut in early life to the development of immunity. Mutat Res. 2007; 622 (1-2), 58–69.

Raoult D. Obesity pandemics and the modification of digestive bacterial flora. Eur J Clin MicrobiolDis. 2008;27(8):631-4.

46. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-3.

Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2005;102(31):11070-5

Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol. 2007;73(4):1073-8.

Backhed F, Ding H, Wang T, et al: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 1 01: 1 5718–15723.

Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 1 04: 979– 984.

Iwamoto Y, Nishimura F, Nakagawa M, et al: The effect of antimicrobial periodontal treatment on circulating tumor ne-crosis factor-alpha and glycated hemoglobin level in patients with type 2 diabetes. J Periodontol 2001; 7 2: 774–778.

143. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes. 2008;32(Suppl 7):S52-4.

Sanz Y, Santacruz A, Dalmau J. Influencia de la mi-crobiota intestinal en la obesidad y las alteraciones del metabolismo. Acta Pediatr Esp 2009;67:437-42.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxaemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-72.

. Amar J, Burcelin R, Ruidavets J, Cani P, Fauvel J, Alessi M, et al. Energy intake is associated with endotoxemia in appar-ently healthy men. Am J Clin Nutr 2008; 87: 1219-23

Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterol 2002;122:531-44.

Morales P, Brignardello J, Gotteland M. La micro-biota intestinal: Un nuevo actor en el desarrollo de la obesidad. Rev Med Chil 2010;138:1020-7.

Speliotes EK et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index 2010 Nov;42 (11):937-48. doi: 10.1038/ng.686. Epub 2010 Oct 10.

Almeida J, Galhenage S, Yu J, Kurtovic J, Riordan SM. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol. 2006 Mar 14;12(10):1493-502

Quigley EM. Bacteria: a new player in gastrointestinal motility disorders? infections, bacterial overgrowth, and pro-biotics. Gastroenterol Clin North Am. 2007 Sep;36(3):735-48

Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. Ageing Res Rev. 2010 Apr;9(2):107-16.

Schrezenmeir J, Vrese M. Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr 2001;73:361S-4S.

Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49:821-30

Jenkins D, Kendall C, Vuksan V. Inulin, oligo-fructose, and intestinal function. J Nutr 1999; 129:1431S-33S.